Fri Sep 7 06:11:48 200717

Fetching...
 
YOU ARE HERE: Homepage > Newsdesk > Article
S.Africa tests first new TB vaccine in 80 years
27 Jul 2007 23:01:07 GMT
Source: Reuters
By Ben Hirschler

LONDON, July 28 (Reuters) - The first new vaccine against tuberculosis in more than 80 years has entered mid-stage trials in South Africa, where the killer disease is rife, scientists said on Saturday.

If the tests are successful, a new shot against M. tuberculosis (TB) bacteria could be available within eight years.

The vaccine was developed by researchers at Oxford University, who are now studying it in Phase II studies in the Western Cape. Despite widespread vaccination, one in 100 infants in the Western Cape suffers from TB disease, underscoring the need for better prevention.

The current standard vaccine for TB is Bacille Calmette-Guerin, or BCG, which provides some protection against severe forms of the disease in children but is unreliable against pulmonary TB, the most common type.

TB is second only to HIV/AIDS as the world's most deadly infectious disease, killing around 1.7 million people a year, and the emergence of strains that are resistant to antibiotics has increased the problem.

"The rise in the number of cases of multi-drug resistant forms of TB plus the increasing number of cases of TB in people living with HIV means a new vaccine is essential," the vaccine's co-developer, Dr Helen McShane, said.

"We can no longer rely on antibiotics to treat the disease -- we need to help the body's immune system prevent disease."

McShane and her colleagues received funding for their trials from the Wellcome Trust medical charity, which provides cash for research that is of potential benefit to public health but has not yet secured financing from commercial backers.

The new vaccine, known as MVA85A, works in tandem with the BCG shot and acts as a booster to the older vaccine. Previous tests have already shown it produces a very high immune response but the key is to show it actually prevents disease.

The vaccine's developers declined to comment on the possible future involvement of major drug companies in the programme. Leading vaccine producers include GlaxoSmithKline <GSK.L>, Sanofi-Aventis <SASY.PA> and Merck & Co. <MRK.N>.
AlertNet news is provided by

Delicio.us  |   Digg  |   NewsVine  |   Reddit                                                                                  Permalink


Bush offers North Korea peace treaty if disarms
Web site says it will show new bin Laden video
Myanmar junta blames exiles for unrest
TEXT-Bush's speech to APEC business summit
Mexican trucks granted authority to operate in US
Grand Designs grows a 'greener' garden for the world's poor
IMC Responds to Deadly Cholera Outbreak in Iraq
Christian Aid plans to double volunteer teacher network
CWS Appeal: Summer 2007 U.S. flooding (broadened response)
Hurricane Katrina anniversary: Two years of rebuilding lives
Thumb for /thefacts/imagerepository/RTRPICT/2007-09-07T011753Z_01_WAS121_RTRIDSP_2_ASIANELEPHANT_mainimage.jpg|/thenews/pictures/WAS121.htm
Thumb for /thefacts/imagerepository/RTRPICT/2007-09-07T011712Z_01_WAS120_RTRIDSP_2_ASIANELEPHANT_mainimage.jpg|/thenews/pictures/WAS120.htm
Thumb for /thefacts/imagerepository/RTRPICT/2007-08-30T104917Z_01_JOH01R_RTRIDSP_2_GERMANY-TRAIN_mainimage.jpg|/thenews/pictures/JOH01R.htm
Thumb for /thefacts/imagerepository/RTRPICT/2007-08-20T154406Z_01_COL101_RTRIDSP_2_SRILANKA_mainimage.jpg|/thenews/pictures/COL101.htm
Thumb for /thefacts/imagerepository/RTRPICT/2007-08-19T173920Z_01_HOU06_RTRIDSP_2_STORM-DEAN_mainimage.jpg|/thenews/pictures/HOU06.htm

Shanthi, a female Asian elephant weighing about 9,000 pounds (4,082 kg) follows caretaker Sean's directions during an elephant training demonstration at the Smithsonian National Zoo in Washington, September 6, 2007. Shanthi came from Sri Lanka, where she was rehabilitated at the Pinnewela Elephant Orphanage. She was given to the National Zoo as a gift from the children of Sri Lanka in 1976.



URL: http://www.alertnet.org/thenews/newsdesk/L27834498.htm

For our full disclaimer and copyright information please visit http://www.alertnet.org